MedTrace Logo

Ultrasound-guided Injection for DeQuervain's

NCT02038634 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2022-12-28

Study results available
· View outcomes & findings →

Summary

The investigators aim to perform a prospective study to evaluate the effectiveness of blind corticosteroid injections to US-guided injections for the treatment of de Quervain's disease. The results of the study will be used to validate current injection protocols or support the incorporation of ultrasonography to treat the disease.

Conditions

  • DeQuervain's Tenosynovitis

Interventions

DRUG

Betamethasone

DEVICE

Ultrasound

Ultrasound guided injection using GE Healthcare LOGIQ e Ultrasound

Sponsors & Collaborators

  • Medical College of Wisconsin

    lead OTHER

Principal Investigators

  • Steven Grindel, MD · MCW/Froedtert Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-08-05
Primary Completion
2021-03-15
Completion
2021-03-15

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02038634 on ClinicalTrials.gov